<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1380">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350736</url>
  </required_header>
  <id_info>
    <org_study_id>0183</org_study_id>
    <secondary_id>2020-000577-24</secondary_id>
    <nct_id>NCT04350736</nct_id>
  </id_info>
  <brief_title>First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and
      pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Actual">June 24, 2020</completion_date>
  <primary_completion_date type="Actual">June 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>double-blind, randomized, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of SAD of TD-0903: Adverse Events</measure>
    <time_frame>Day 1 to Day 8</time_frame>
    <description>Number and severity of treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of MAD of TD-0903: Adverse Events</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <description>Number and severity of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax</measure>
    <time_frame>Day 1 through Day 4</time_frame>
    <description>Multiple PK variables of TD-0903 will be assessed during SAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC</measure>
    <time_frame>Day 1 through Day 9</time_frame>
    <description>Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax</measure>
    <time_frame>Day 1 through Day 9</time_frame>
    <description>Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax</measure>
    <time_frame>Day 1 through Day 9</time_frame>
    <description>Multiple PK variables of TD-0903 will be assessed during MAD and may include, but are not limited to: Time to reach maximum observed concentration (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Acute Lung Injury (ALI) Associated With COVID-19</condition>
  <condition>Inflammatory Lung Conditions Associated With COVID-19</condition>
  <arm_group>
    <arm_group_label>TD-0903 for SAD (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 out of 8 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-0903 for MAD (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive TD-0903</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 out of 10 subjects per cohort (up to 3 cohorts) will be randomized to receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-0903</intervention_name>
    <description>Study drug to be administered by inhalation</description>
    <arm_group_label>TD-0903 for MAD (Part B)</arm_group_label>
    <arm_group_label>TD-0903 for SAD (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to be administered by inhalation</description>
    <arm_group_label>Placebo for MAD (Part B)</arm_group_label>
    <arm_group_label>Placebo for SAD (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening and weighs at least 50 kg.

          -  Medically healthy with no clinically significant medical history, physical
             examination, spirometry, vital signs or ECGs.

          -  Forced expiratory volume in 1 second (FEV1) ≥80%.

          -  No clinically significant abnormalities in the results of laboratory evaluations.

          -  Female subjects must be either of non-childbearing potential or if of childbearing
             potential, subject must not be pregnant or breastfeeding, and must agree to use a
             highly effective birth control method.

          -  Male subjects must agree to use condoms, in addition to the use of highly effective
             pregnancy prevention measures with female partners of childbearing potential.

          -  Understands the correct technique for the use the nebulizer device(s).

          -  Other inclusion criteria apply

        Exclusion Criteria:

          -  History or presence of clinically significant medical or psychiatric condition.

          -  Abnormal ECG measurements at Screening.

          -  Any signs of respiratory tract infection within 6 weeks of Screening.

          -  Subject who has a current bacterial, parasitic, fungal, or viral infection; any
             infection requiring hospitalization or intravenous antibiotics within 6 months prior
             to Screening.

          -  Positive test for SARS-CoV-2

          -  Subject has any condition of the oro-laryngeal or respiratory tract.

          -  Uses or has used tobacco or nicotine-containing products (e.g., cigarettes, cigars,
             chewing tobacco, snuff, patches etc.) within 6 months prior to screening

          -  Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theravance Biopharma Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute lung injury</keyword>
  <keyword>ALI</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus Disease 2019</keyword>
  <keyword>inflammatory lung conditions</keyword>
  <keyword>Inflammatory lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

